Mainstay Medical chief executive Peter Crosby: “our existing investor group is very supportive of Mainstay”

Dublin-listed Mainstay Medical, a company that is targeting chronic back pain with an implantable device, is expecting to seek further funding in the (...)

As Theresa May’s trigger finger gets itchy – article 50 is due to be activated by the end of the month – the lion’s share of intrigue will be  on how the next two years might alter Irish-UK trade relations. Photograph: Bloomberg

MONDAY Results: YouGov Indicators: Euro zone labour cost index and wage growth (Q4) Meetings: Girls in Tech launch event (Bank of Ireland, Grand(...)

Mainstay Medical’s has announced the first sale of its ReActiv8 neurostimulator to treat chronic lower back pain  at a hospital in Koblenz, Germany

Mainstay Medical, the Irish developer of a breakthrough device to treat chronic lower back pain, has made its first commercial sale. The company’s Re(...)

Mainstay Medical chief executive Peter Crosby. Photograph: Nick Bradshaw

Medical device firm Mainstay Medical has sought approval to market in Australia its implantable device for chronic low back pain. The Dublin-listed(...)

Early-stage companies raised seed capital of €57m  in the first nine months of this year, equivalent to 8%  of all funds raised

Investment in Irish technology firms has more than doubled over the last two years, according to new figures which show that companies raised a record(...)

Mainstay Medical’s chief executive Peter Crosby: The company  raised €30 million in funding in June through a placing of new shares in the business, with the money to be used to drive the commercialisation of its flagship neurostimulator ReActiv8

Dublin-listed Mainstay Medical, developers of an implantable device that targets chronic lower-back pain, has added another US patent to its portfoli(...)

Peter Crosby, CEO of Mainstay Medical. The company is targeting chronic lower back pain with an implantable device

Dublin-listed Mainstay Medical, a company targeting chronic lower back pain with an implantable device, has reported an operating loss of almost $8 mi(...)

Mainstay Medical chief executive Peter Crosby.

Dublin-listed Mainstay Medical, a company targeting chronic lower back pain with an implantable device, reported a $13.2 million (€11.8 million) loss(...)

Peter Sandys, managing partner at Seroba Life Sciences, and Aidan Meagher, head of life sciences at EY: “It is essential that we continue to nurture high potential start-ups and give them the opportunity to grow their business”

At an event in Dublin this week, more than 50 medtech start-ups will pitch for funding from venture capital firms with more than €13 billion in funds (...)

Peter Crosby, chief executive of Mainstay Medical

Dublin-listed Mainstay Medical, which is targeting chronic lower back pain with an implantable device, has drawn down €10.5 million of the €15.5 milli(...)

  • « First
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »